NRIX (Nurix Therapeutics) Float Percentage Of Total Shares Outstanding: 98.90% (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NRIX Nurix Therapeutics Inc NRIX
61 GF Score
Price $25.22
GF Value $6.40
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Nurix Therapeutics Float Percentage Of Total Shares Outstanding?

Nurix Therapeutics NRIX +0.36% 61 Float Percentage Of Total Shares Outstanding is 98.90% as of Aug. 07, 2026. GuruFocus rates NRIX with a GF Score™ of 61/100 and a GF Value™ of $6.40 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nurix Therapeutics's float shares is 102.63 Mil. Nurix Therapeutics's total shares outstanding is 103.78 Mil. Nurix Therapeutics's float percentage of total shares outstanding is 98.90%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nurix Therapeutics's Insider Ownership is 0.53%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nurix Therapeutics's Institutional Ownership is 113.10%.

NRIX
61GF Score
Nurix Therapeutics Inc NRIX
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nurix Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Nurix Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=102.63/103.78
=98.90%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 98.90% mean?
Nurix Therapeutics (NRIX) has a Float Percentage Of Total Shares Outstanding of 98.90% as of Aug. 07, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Nurix Therapeutics and its competitors.
Is Nurix Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Nurix Therapeutics' current Float Percentage Of Total Shares Outstanding is 98.90%. Overall, Nurix Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nurix Therapeutics' Float Percentage Of Total Shares Outstanding compare to PHVS and NKTR?
Nurix Therapeutics' Float Percentage Of Total Shares Outstanding of 98.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Nurix Therapeutics and its competitors. Nurix Therapeutics's current Float Percentage Of Total Shares Outstanding is 98.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nurix Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nurix Therapeutics (NRIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.40, compared to a current price of $25.22 — trading 294.1% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 98.90%. Nurix Therapeutics' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Nurix Therapeutics (NRIX), the current Float Percentage Of Total Shares Outstanding is 98.90% as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nurix Therapeutics (NRIX) Overvalued in 2026?

Based on GuruFocus' analysis, Nurix Therapeutics stock appears to be overvalued. The current stock price of $25.22 is trading 294.1% above its estimated GF Value™ of $6.40. GuruFocus considers Nurix Therapeutics to be Significantly Overvalued.

Key valuation signals for NRIX:

  • Float Percentage Of Total Shares Outstanding: 98.90%
  • GF Value™: $6.40 vs. price of $25.22 (294.1% above fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the NRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nurix Therapeutics Business Description

Address 1600 Sierra Point Parkway, Brisbane, CA, USA, 94005
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
61GF Score

Get the complete analysis for NRIX

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.22
Price
$6.40
GF Value